UNSPSC 51272112: Betoxycaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C19H32N2O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8II47759Z3. Most nations, for tariff and trade purposes, schedule betoxycaine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, BETOXYCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betoxycaine hydrochloride bears US NLM identifiers UMLS ID C2347004 and NCI Concept Code C73801. SMILES: CCCCOC1CCC(CC1N)C(=O)OCCOCCN(CC)CC.CL.

UNSPSC 51272112 Betoxycaine hydrochloride is a Commodity code that in recent state and local procurement activity has been tagged to a narrower set of pharmaceutical procurement opportunities that diverge significantly from the code's nominal scope. The recent opportunities solicited under this code include naloxone and drug deactivation systems procurement, therapeutic pharmacy initiatives involving direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The issuing bodies reflect a mix of county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the jurisdictions with recent solicitation activity under this code.

Recent activity is geographically concentrated in the Southeast and Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the procurement includes a two-year initial term with an optional one-year renewal, E-Verify compliance, and drug-free workplace certification. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program focused on establishing direct relationships between the state's pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and contract pricing weighted 75 percent on competitiveness and 10 percent on fixed pricing for the contract term.